Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, extension protocol designed to allow patients to continue to receive
belinostat treatment after they have completed the protocol-specified assessments and
procedures in a Spectrum sponsored belinostat study and have not met the criteria for
treatment discontinuation in those studies. This extension of belinostat treatment allowance
is not a part of the primary efficacy assessments for those trials. The extension is intended
to provide all possible benefits to patients who are having a positive response to belinostat
and must be under the Investigator's care. The additional treatment is optional and
voluntary.